Glaxo sells 25 brands to Aspen
GlaxoSmithKline, Britain's biggest pharmaceuticals company, has pocketed £172m from the sale of 25 drugs to Australia's Aspen.
It is part of the drug maker's clear-out of some of its smaller medicines and over-the-counter treatments. The brands it sold yesterday include the herpes treatment Valtrex, epilepsy drug Lamictal and the antibiotic Amoxil. The 25 products together bought in sales of £83m last year.
The company said its focus was now on priority brands, products and pipeline opportunities that has long-term growth potential.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies